Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study. [electronic resource]
Producer: 20091231Description: 1716-23 p. digitalISSN:- 1879-114X
- Administration, Inhalation
- Adrenergic beta-Agonists -- administration & dosage
- Aged
- Area Under Curve
- Bronchodilator Agents -- administration & dosage
- Cross-Over Studies
- Dose-Response Relationship, Drug
- Double-Blind Method
- Ethanolamines -- administration & dosage
- Female
- Forced Expiratory Volume -- drug effects
- Formoterol Fumarate
- Humans
- Least-Squares Analysis
- Male
- Middle Aged
- Nebulizers and Vaporizers
- Pulmonary Disease, Chronic Obstructive -- drug therapy
- Severity of Illness Index
- Time Factors
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.